Nebivolol Teva (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivolol Teva, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nebivolol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

Hypertension: lowers systemic blood pressure by reducing cardiac output and promoting nitric‑oxide mediated vasodilation. Heart failure: improves left‑ventricular ejection fraction and reduces the risk of hospitalization in patients with reduced‑ejection‑fraction heart failure.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Nasal congestion or rhinorrhoea. - Nausea or mild gastrointestinal upset. - Tinnitus or ringing in the ears.

Serious or Rare Side Effects: - Severe bradycardia or heart block. - Marked hypotension leading to syncope. - Bronchospasm in patients with reactive airway disease. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Hepatic enzyme elevation or liver injury. - Worsening heart failure or pulmonary edema.

Before initiating Nebivolol, clinicians should assess patient‑specific factors and monitor for potential complications.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess cardiac function: evaluate heart rate and rhythm regularly. Use caution in asthma or COPD: β‑blockade may precipitate bronchospasm. Review concomitant beta‑blockers: avoid additive cardiac depression. Adjust in renal impairment: dose may need modification based on renal function. Store at room temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes; understanding the severity helps guide clinical decisions.

Major Interactions (Avoid): - Non‑selective beta‑blockers: risk of excessive β‑blockade. - Calcium‑channel blockers (verapamil, diltiazem): may cause profound bradycardia. - Other antihypertensives: additive hypotensive effect. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels. - Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - NSAIDs: may reduce antihypertensive efficacy. - Certain antidepressants (sertraline): observe for heart‑rate changes.